Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;55(8):1019-1025.
doi: 10.1016/j.dld.2023.03.013. Epub 2023 May 20.

Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol

Romain Coriat  1 , Vincent Sibaud  2 , Vincent Bourgeois  3 , Sylvain Manfredi  4 , Pascal Artru  5 , Isabelle Trouilloud  6 , Michael Kremliovsky  7 , Pierre Arvis  8 , Mario Di Palma  9
Affiliations

Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol

Romain Coriat et al. Dig Liver Dis. 2023 Aug.

Abstract

Background: The FACET study is a prospective, open-label, low risk interventional clinical trial aiming at exploring the fitness-for-purpose and usability of an electronic device suite for the detection of hand-foot skin reaction symptoms in patients with metastatic colorectal cancer treated with regorafenib.

Methods: 38 patients with metastatic colorectal cancer are being selected in 6 centers in France, and will be followed for 2 regorafenib treatment cycles, or for approximately 56 days. The electronic device suite includes connected insoles and a mobile device equipped with a camera and a companion application with electronic patient-reported outcomes questionnaires and educational material. The FACET study is intended to provide information useful for the improvement of the electronic device suite and its usability before the testing of its robustness in a larger follow-up study. This paper describes the protocol of the FACET study and discusses the limitations to consider for the implementation of digital devices in real-life practice.

Keywords: Digital device; Metastatic colorectal cancer; Patient-reported outcomes; Regorafenib treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Romain Coriat acted as consultant for Bayer, Amgen, AAA, Ipsen, Merck, BMS, Servier, Sanofi, and Novartis. Romain Coriat, Vincent Sibaud, and Mario Di Palma are members of the study Steering Committee. Michael Kremliovsky and Pierre Arvis are Bayer employees. The other authors declare no competing interests.

MeSH terms

LinkOut - more resources